Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accelerated Approval Great For “Me-Too” Products, FDA Says

Executive Summary

CDER’s Bob Temple explains how competitors could actually help speed up a drug approval but also hold a product to a higher standard.

You may also be interested in...



Genetic Diseases Could See Indication Expansions Through Accelerated Approval

Accelerated approvals likely to increase, particularly for cancer, predicts FDA’s Temple.

A User Guide To FDA’s Expedited Programs For Serious Conditions

A handy side-by-side chart shows the criteria, advantages and timelines for the fast-track, breakthrough therapy and priority review designations and the accelerated approval pathway.

Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data

Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel